---
figid: PMC10995224__fphar-15-1173240-g002
figtitle: Signaling pathway that was affected by ridaforolimus
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10995224
filename: PMC10995224__fphar-15-1173240-g002.jpg
figlink: /pmc/articles/PMC10995224/figure/F2
number: F2
caption: 'Overview of the signaling pathway that was affected by ridaforolimus. AKT:
  protein kinase B; mTORC1: mammalian target of rapamycin complex 1; mTORC2: mammalian
  target of rapamycin complex 2; 4E-BP1: eukaryotic translation initiation factor
  4E-binding protein 1; PDK1: phosphoinositide-dependent kinase-1; PI3K: phosphatidylinositol-4,5-bisphosphate-3-kinase;
  PIP3: phosphatidylinositol (3,4,5)-trisphosphate (Liu et al., 2009; Stroh et al.,
  2012a; Arash Boroumand Nasr et al., 2015); PTEN: phosphatase and tensin homolog;
  S6K: ribosomal protein S6 kinase; DEPTOR: death domain-containing mTOR interacting
  protein; mTOR: mammalian target of rapamycin; Raptor: regulatory associated protein
  of mTOR; PDCD4: programmed cell death 4; TSC1: tuberous sclerosis complex 1; TSC2:
  tuberous sclerosis complex 2; PRAS40: proline-rich AKT substrate 40 kDa; PHLPP1/2:
  PH domain leucine-rich repeat protein phosphatase; PP2A: protein phosphatase 2A;
  and Rictor: rapamycin-insensitive companion of mTOR'
papertitle: 'Clinical research progress of ridaforolimus (AP23573, MK8668) over the
  past decade: a systemic review'
reftext: Lumin Wang, et al. Front Pharmacol. 2024;15(NA).
year: '2024'
doi: 10.3389/fphar.2024.1173240
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: ridaforolimus | mTOR inhibitors | signaling pathway | drug combination |
  adverse events
automl_pathway: 0.9541068
figid_alias: PMC10995224__F2
figtype: Figure
redirect_from: /figures/PMC10995224__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10995224__fphar-15-1173240-g002.html
  '@type': Dataset
  description: 'Overview of the signaling pathway that was affected by ridaforolimus.
    AKT: protein kinase B; mTORC1: mammalian target of rapamycin complex 1; mTORC2:
    mammalian target of rapamycin complex 2; 4E-BP1: eukaryotic translation initiation
    factor 4E-binding protein 1; PDK1: phosphoinositide-dependent kinase-1; PI3K:
    phosphatidylinositol-4,5-bisphosphate-3-kinase; PIP3: phosphatidylinositol (3,4,5)-trisphosphate
    (Liu et al., 2009; Stroh et al., 2012a; Arash Boroumand Nasr et al., 2015); PTEN:
    phosphatase and tensin homolog; S6K: ribosomal protein S6 kinase; DEPTOR: death
    domain-containing mTOR interacting protein; mTOR: mammalian target of rapamycin;
    Raptor: regulatory associated protein of mTOR; PDCD4: programmed cell death 4;
    TSC1: tuberous sclerosis complex 1; TSC2: tuberous sclerosis complex 2; PRAS40:
    proline-rich AKT substrate 40 kDa; PHLPP1/2: PH domain leucine-rich repeat protein
    phosphatase; PP2A: protein phosphatase 2A; and Rictor: rapamycin-insensitive companion
    of mTOR'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD4
  - RPS6KB1
  - RPS6KB2
  - ANXA6
  - UBASH3B
  - TSC2
  - MTOR
  - AKT1S1
  - AKT1
  - AKT2
  - AKT3
  - PHLPP1
  - PHLPP2
  - PTPA
  - PTEN
  - MAPKAP1
  - RICTOR
  - MLST8
  - DEPTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - Raptor
  - Ridaforolimus
---
